| Literature DB >> 24907411 |
Diego A Vargas-Inchaustegui1, Iskra Tuero1, Venkatramanan Mohanram1, Thomas Musich1, Poonam Pegu2, Antonio Valentin3, Yongjun Sui4, Margherita Rosati3, Jenifer Bear5, David J Venzon6, Viraj Kulkarni5, Candido Alicea5, Guy R Pilkington5, Namal P M Liyanage2, Thorsten Demberg1, Shari N Gordon2, Yichuan Wang4, Alison E Hogg4, Blake Frey4, L Jean Patterson1, Janet DiPasquale1, David C Montefiori7, Niranjan Y Sardesai8, Steven G Reed9, Jay A Berzofsky4, Genoveffa Franchini2, Barbara K Felber5, George N Pavlakis3, Marjorie Robert-Guroff10.
Abstract
Combinatorial HIV/SIV vaccine approaches targeting multiple arms of the immune system might improve protective efficacy. We compared SIV-specific humoral immunity induced in rhesus macaques by five vaccine regimens. Systemic regimens included ALVAC-SIVenv priming and Env boosting (ALVAC/Env); DNA immunization; and DNA plus Env co-immunization (DNA&Env). RepAd/Env combined mucosal replication-competent Ad-env priming with systemic Env boosting. A Peptide/Env regimen, given solely intrarectally, included HIV/SIV peptides followed by MVA-env and Env boosts. Serum antibodies mediating neutralizing, phagocytic and ADCC activities were induced by ALVAC/Env, RepAd/Env and DNA&Env vaccines. Memory B cells and plasma cells were maintained in the bone marrow. RepAd/Env vaccination induced early SIV-specific IgA in rectal secretions before Env boosting, although mucosal IgA and IgG responses were readily detected at necropsy in ALVAC/Env, RepAd/Env, DNA&Env and DNA vaccinated animals. Our results suggest that combined RepAd priming with ALVAC/Env or DNA&Env regimen boosting might induce potent, functional, long-lasting systemic and mucosal SIV-specific antibodies. Published by Elsevier Inc.Entities:
Keywords: Functional antibody activities; Memory B cells; Mucosal and systemic humoral immunity; Poxvirus-, adenovirus-, and DNA-based vaccines; Simian Immunodeficiency Virus
Mesh:
Substances:
Year: 2014 PMID: 24907411 PMCID: PMC4102324 DOI: 10.1016/j.clim.2014.05.008
Source DB: PubMed Journal: Clin Immunol ISSN: 1521-6616 Impact factor: 3.969